{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-007114","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2026-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.909737+00:00","generated_at":"2026-05-16T03:15:05.462675+00:00","sec_items":["7.01","2.02","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA clears Precision BioSciences' IND for PBGENE-DMD gene editing therapy for DMD","bullets":["FDA Study May Proceed allows initiation of clinical trial site activation for Phase 1/2 FUNCTION-DMD study in ambulatory DMD patients.","PBGENE-DMD is an in vivo gene excision approach targeting mutations in exons 45-55, covering ~60% of DMD patients.","Aims to restore near full-length dystrophin (80% of full-length), larger than existing micro-dystrophin constructs (~34%).","Company plans to activate first US clinical site in the first half of 2026.","Virtual investor event scheduled for March after MDA conference with key opinion leaders and patient advocates."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-007114","json":"https://secwatch.observer/filing/0001628280-26-007114.json","markdown":"https://secwatch.observer/filing/0001628280-26-007114.md","text":"https://secwatch.observer/filing/0001628280-26-007114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026007114/0001628280-26-007114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026007114/dtil-20260211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:15:05.462675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}